Filing Flows › Intellia Therapeutics (NTLA) › R&D spending
Intellia Therapeutics (NTLA) R&D spending by quarter
Intellia Therapeutics' R&D spending was $83.3M in Q3 2026 (third quarter 2026), +0.9% from Q2 2026. Over the last 7 quarters it ranged from $80.7M (Q1 2026) to $108M (Q1 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $83.3M | +0.9% | -12% |
| Q2 2026 | $82.6M | +2% | -15% |
| Q1 2026 | $80.7M | -9% | -26% |
| Q4 2025 | $88.7M | -6% | — |
| Q3 2025 | $94.7M | -2% | — |
| Q2 2025 | $97.0M | -11% | — |
| Q1 2025 | $108M | — | — |
Q3 2026 at a glance
Intellia Therapeutics, Q3 2026: revenue $7.2M (-48% year over year), net loss $127M, operating cash flow −$85.4M. The chart follows the revenue to costs, profit and cash.
Questions
What is Intellia Therapeutics' R&D spending?
Intellia Therapeutics' R&D spending was $83.3M in Q3 2026 (third quarter 2026), +0.9% from Q2 2026.
How has Intellia Therapeutics' R&D spending changed?
Over the last 7 quarters it ranged from $80.7M (Q1 2026) to $108M (Q1 2025).